Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus ranibizumab for exudative age-related macular degeneration
2010-021968-15Phase 2Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Aug 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and ranibizumab in exudative macular degeneration (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Started Aug 2010; status: active.
02
Drugs
bevacizumabranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2010-021968-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021968-15.